These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30175979)

  • 41. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovering Hair Biomarkers of Alzheimer's Disease Using High Resolution Mass Spectrometry-Based Untargeted Metabolomics.
    Su YH; Chang CW; Hsu JY; Li SW; Sung PS; Wang RH; Wu CH; Liao PC
    Molecules; 2023 Feb; 28(5):. PubMed ID: 36903413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease.
    Greenberg N; Grassano A; Thambisetty M; Lovestone S; Legido-Quigley C
    Electrophoresis; 2009 Apr; 30(7):1235-9. PubMed ID: 19288586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease.
    Kang S; Jeong H; Baek JH; Lee SJ; Han SH; Cho HJ; Kim H; Hong HS; Kim YH; Yi EC; Seo SW; Na DL; Hwang D; Mook-Jung I
    J Alzheimers Dis; 2016 Jul; 53(4):1563-76. PubMed ID: 27392853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker Panel for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment: A Pilot Study.
    Yilmaz A; Ugur Z; Bisgin H; Akyol S; Bahado-Singh R; Wilson G; Imam K; Maddens ME; Graham SF
    Metabolites; 2020 Aug; 10(9):. PubMed ID: 32878308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
    Wang L;
    Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory.
    Moodley K; Minati L; Contarino V; Prioni S; Wood R; Cooper R; D'Incerti L; Tagliavini F; Chan D
    Hippocampus; 2015 Aug; 25(8):939-51. PubMed ID: 25605659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brain glutathione levels--a novel biomarker for mild cognitive impairment and Alzheimer's disease.
    Mandal PK; Saharan S; Tripathi M; Murari G
    Biol Psychiatry; 2015 Nov; 78(10):702-10. PubMed ID: 26003861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer's Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?
    Oberacher H; Arnhard K; Linhart C; Diwo A; Marksteiner J; Humpel C
    J Alzheimers Dis; 2017; 57(2):493-504. PubMed ID: 28269764
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS.
    Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y
    Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Periodontal Status and Saliva Metabolic Signature in Patients with Alzheimer's Disease.
    Yang Y; Lv J; Bai H; Ren L; Yang J; Ding Y; Liu C; Chen X
    J Alzheimers Dis; 2023; 95(2):603-613. PubMed ID: 37424468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.
    Leifert WR; Nguyen T; Rembach A; Martins R; Rainey-Smith S; Masters CL; Ames D; Rowe CC; Macaulay SL; François M; Fenech MF;
    J Alzheimers Dis; 2015; 48(2):443-52. PubMed ID: 26402008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.
    Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A
    Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease.
    Graham SF; Chevallier OP; Elliott CT; Hölscher C; Johnston J; McGuinness B; Kehoe PG; Passmore AP; Green BD
    PLoS One; 2015; 10(3):e0119452. PubMed ID: 25803028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
    Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
    JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals.
    Casanova R; Varma S; Simpson B; Kim M; An Y; Saldana S; Riveros C; Moscato P; Griswold M; Sonntag D; Wahrheit J; Klavins K; Jonsson PV; Eiriksdottir G; Aspelund T; Launer LJ; Gudnason V; Legido Quigley C; Thambisetty M
    Alzheimers Dement; 2016 Jul; 12(7):815-22. PubMed ID: 26806385
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-Performance Chemical Isotope Labeling Liquid Chromatography-Mass Spectrometry for Profiling the Metabolomic Reprogramming Elicited by Ammonium Limitation in Yeast.
    Luo X; Zhao S; Huan T; Sun D; Friis RM; Schultz MC; Li L
    J Proteome Res; 2016 May; 15(5):1602-12. PubMed ID: 26947805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.